跳至主要内容
临床试验/NCT02252653
NCT02252653已完成不适用

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Alnylam Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 1,010 人开始时间: 2014年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,010
试验地点
1
主要终点
Proportion of patients with of Transthyretin (TTR) mutations

研究概览

简要总结

The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males or females >18 years old
  • History of evidence suggestive of cardiac amyloidosis
  • Subject is willing and able to comply with protocol required assessments and provide written informed consent

排除标准

  • Known diagnosis of primary (AL) amyloidosis
  • Known diagnosis of hereditary cardiomyopathy or cardiomyopathy due to aortic stenosis
  • Patient is currently pregnant

结局指标

主要结局

Proportion of patients with of Transthyretin (TTR) mutations

时间窗: Baseline

Blood will be sequenced for the presence of TTR gene mutations

次要结局

  • Assessment of the presence of amyloid in tissue(Day 30)
  • Quantification of biomarkers of cardiac function in serum(Day 30)
  • Measurement of echocardiogram parameters(Day 30)
  • New York Heart Association (NYHA) Functional Classification(Day 30)
  • Results from 6-Minute Walk Test(Day 30)

研究者

发起方
Alnylam Pharmaceuticals
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验